Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda

Starting soon · Not applicable

Conditions studied: Medication Adherence, Breast Cancer

In brief

This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.

Key facts

Study ID

NCT07562399

Run by

Dana-Farber Cancer Institute

People needed

224

Starts

2026-09-20

Expected to finish

2028-12-31

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients
• Age 18 or older
• Pathologic confirmation of ER-positive breast cancer
• Clinical or radiographic confirmation of disease localized to the breast and regional lymph nodes
• Within 6-36 months of starting AET
• Have a cellphone capable of receiving text messages.
• Are currently receiving AET at Butaro or satellite clinics.

You may not qualify if…

• Unwilling/Unable to participate
• Unable to comprehend study languages (English or Kinyarwanda)
• Adults unable to consent
• Individuals who are not yet adults (infants, children, teenagers)
• Prisoners
• Pregnant women

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Boston Children's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Butaro Cancer Center of Excellence — Butaro, RN8, Rwanda

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.